The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A Multi-Centre Double-Blind Randomised Placebo-Controlled Trial Of Oral Anticoagulation In Systemic Sclerosis-Related Pulmonary Arterial Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$1,190,521.00
Summary
Scleroderma is an autoimmune disease that shortens life span by over 30 years. The main cause of death is pulmonary arterial hypertension (PAH), a condition of increased pressure in the lung vessels. Even in the era of 'advanced' PAH therapy, only 50% of patients are alive beyond 5 years. Formation of clots in the small blood vessels of the lung plays a major role in the development of PAH. In this clinical trial we aim to determine whether anticoagulation (treatment to prevent clotting) improve ....Scleroderma is an autoimmune disease that shortens life span by over 30 years. The main cause of death is pulmonary arterial hypertension (PAH), a condition of increased pressure in the lung vessels. Even in the era of 'advanced' PAH therapy, only 50% of patients are alive beyond 5 years. Formation of clots in the small blood vessels of the lung plays a major role in the development of PAH. In this clinical trial we aim to determine whether anticoagulation (treatment to prevent clotting) improves survival in scleroderma PAH.Read moreRead less